SHARON, Pa., May 9 /PRNewswire-FirstCall/ -- NanoLogix, Inc., (Pink
Sheets: IFEC), a Nanobiotechnology company engaged in the research,
development and commercialization of technologies for the production of
bacteria and disease testing kits, alternative sources of fuel, cancer therapy
and remediation of toxic materials, announces that preliminary data and
results of a study which confirms laboratory proof-of-concept measurements
have shown it possible to generate hydrogen in high yields via the use and
adaptation of its intellectual property. In this study, the bioreactor
produced biogas consisting of 50% hydrogen by volume, without any trace of
Recently, NanoLogix, Inc. (formerly Infectech, Inc.) signed a feasibility
study with the Department of Environmental Science and Engineering of Gannon
University in Erie, PA to develop a bioreactor which utilizes NanoLogix's
patented bacterial culturing methods in order to produce hydrogen
inexpensively. Hydrogen reacts with oxygen to yield significant amounts of
energy, and has the added benefit of not producing carbon dioxide as a
by-product (the reaction between hydrogen and oxygen simply generates water
vapor). NanoLogix believes they have discovered the most likely method for
low cost production of massive quantities of hydrogen as an alternate energy
source. NanoLogix has ascertained through its patent counsel that additional
patents will be pending beyond those already filed.
NanoLogix, Inc., formerly known as Infectech, Inc.
(http://www.infectech.com), is a technology application innovator of biogas
products and services designed to assist in worldwide energy independence and
reduce pollution from renewable, environmentally-friendly energy sources.
NanoLogix is also engaged in the research and development of diagnostic test
kits designed to be used for the rapid identification of infectious human
diseases. The Company's patents span the identification and antibiotic
sensitivity testing of 34 disease-producing bacteria, including M.
tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and
nocardia. These bacteria are cited as prominent causes of morbidity and
mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally,
NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer
cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a
genetically based induction of "cell suicide" in cells. The Company's 31
patents can be viewed by visiting
The convergence of science, medicine and technology is on the cusp of
yielding extraordinary breakthroughs. Today, patents that were once designed
to identify bacteria have widespread applications across multiple markets. At
the heart of this convergence is nature. All things begin and end with the
building blocks of life. NanoLogix's portfolio of 31 patents have yielded a
method vital to the development of biophasic system devices intended for
medical purposes to cultivate and identify certain pathogenic microorganisms.
The devices contain one or more components that suppress the growth of certain
microorganisms while either promoting or not affecting the growth of other
microorganisms. The FDA registered devices aid in the diagnosis of disease
caused by the pathogenic microorganisms. products, a method for low cost
hydrogen production, a genomic cancer therapy and methods for cleaning up
toxic environments using bioremediation.
NanoLogix's patents have nanotechnology applications in medical
drugs/devices, bio-defense sensors, hydrogen production, cancer treatment and
bioremediation. Nanotechnology applications include Biochips embedded in
small transportable devices for rapid bacteria identification of disease
causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for
rapid environmental microbial monitoring with bio-defense implications. Its
hydrogen bioreactor research is designed to assist in worldwide energy
independence and reduce pollution using renewable, environmentally-friendly
energy sources. NanoLogix's FDA registered diagnostic test kits are designed
to be used for the rapid identification of infectious human diseases and
identify 34 disease-producing bacteria, including Tuberculosis (TB),
Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These
bacteria are cited as prominent causes of morbidity and mortality in patients
with cancer, cystic fibrosis, and AIDS, as well as in patients undergoing
surgery. Additionally, NanoLogix owns a patent for the nontoxic induction of
apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a
method for inducing a genetically based induction of "cell suicide" in cells.
It therefore serves as the foundation for cancer therapy. NanoLogix's other
patents include technology designed for use in the bioremediation of
contaminated soil and water.
This press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix, Inc., and members of
its management as well as the assumptions on which such statements are based.
Prospective investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and uncertainties,
and that actual results may differ materially from those contemplated by such
forward-looking statements. Important factors currently known to management
that could cause actual results to differ materially from those in forward-
statements include fluctuation of operating results, the ability to compete
successfully and the ability to complete before-mentioned transactions. The
company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated
events or changes to future operating results.
SOURCE NanoLogix, Inc.